Latest News and Press Releases

TARRYTOWN, N.Y. and WASHINGTON, D.C., March 12, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Achyuta...

Full Year Total Revenue Grew 14% to $18.2 Million, Marking Highest Level Since 2016 Annual Recurring Revenue (ARR) increased 23% to Record $12 Million, Exceeding Total Revenue Reported at Beginning...

Dublin, March 12, 2024 (GLOBE NEWSWIRE) -- The "Pipeline Transport Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The pipeline transport market has grown...

Recently completed financing provides sufficient funds for near-term Parkinson’s Disease priority Plans for Phase 2b trial of NE3107 as first-line monotherapy for Parkinson’s Disease being...

WINNIPEG, Manitoba, March 08, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that at the Bioscience Association of Manitoba...

MENLO PARK, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and...

Reported $456.3 million in cash resources as of December 31, 2023, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Initiation of...

Achieved full year 2023 Contribution ex-TAC and Adjusted EBITDA above the midpoints of the Company’s guidance Grew programmatic revenue 9% for full year 2023 vs. 2022; expanded programmatic revenue...

- Record fourth quarter 2023 CGuard EPS revenue of $1.76 million increased 71.6% over fourth quarter 2022 - - Announced positive 30-day data from the Company’s ongoing U.S. Investigational Device...

NXP800 preliminary data update expected this month from the Phase 1b study in platinum resistant, ARID1a mutated ovarian cancer, a program that has been granted Fast Track Designation by the FDANXP800...